Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059982 · ClinicalTrials.gov registry record · Phase 2
Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00059982 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group.
The verdict
NCT00059982, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Perifosine may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced, unresectable, or metastatic pancreatic cancer.
Interventions
- DRUG perifosine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-07 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00059982
The ClinicalTrials.gov registry entry for NCT00059982 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which perifosine is the first listed.
NCT00059982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00059982 about?
NCT00059982 is a clinical study titled "Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer". RATIONALE: Perifosine may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced, unresectable, or metastatic pancreatic cancer.
What is the current status of trial NCT00059982?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-07. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00059982?
The interventions under investigation include: perifosine (DRUG).
Who is sponsoring clinical trial NCT00059982?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.